These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 29921693)

  • 21. Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.
    Pang X; Sun X; Gu Y; He X; Gong K; Song S; Zhang J; Xia J; Liu Z; Cui Y
    Signal Transduct Target Ther; 2023 Feb; 8(1):60. PubMed ID: 36759595
    [No Abstract]   [Full Text] [Related]  

  • 22. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics.
    Zhang J; Hu Z; Horta CA; Yang J
    Semin Cancer Biol; 2023 Jan; 88():46-66. PubMed ID: 36521737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Interleukin-1 family in bone metastasis of prostate cancer.
    Tong Y; Cao Y; Jin T; Huang Z; He Q; Mao M
    Front Oncol; 2022; 12():951167. PubMed ID: 36237303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss.
    Mejía-Hernández JO; Keam SP; Saleh R; Muntz F; Fox SB; Byrne D; Kogan A; Pang L; Huynh J; Litchfield C; Caramia F; Lozano G; He H; You JM; Sandhu S; Williams SG; Haupt Y; Haupt S
    Cell Death Dis; 2022 Sep; 13(9):777. PubMed ID: 36075907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.
    Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p.
    Chen DL; Sheng H; Zhang DS; Jin Y; Zhao BT; Chen N; Song K; Xu RH
    Mol Cancer; 2021 Dec; 20(1):166. PubMed ID: 34911533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell Plasticity and Prostate Cancer: The Role of Epithelial-Mesenchymal Transition in Tumor Progression, Invasion, Metastasis and Cancer Therapy Resistance.
    Papanikolaou S; Vourda A; Syggelos S; Gyftopoulos K
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression.
    Mukherjee S; Sudandiradoss C
    Funct Integr Genomics; 2021 Jul; 21(3-4):451-472. PubMed ID: 34184132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
    Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
    J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.
    Bahmad HF; Jalloul M; Azar J; Moubarak MM; Samad TA; Mukherji D; Al-Sayegh M; Abou-Kheir W
    Front Genet; 2021; 12():652747. PubMed ID: 33841508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Curdione Induces Antiproliferation Effect on Human Uterine Leiomyosarcoma
    Wei C; Li D; Liu Y; Wang W; Qiu T
    Front Oncol; 2021; 11():637024. PubMed ID: 33718227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.
    Sun Y; Jing J; Xu H; Xu L; Hu H; Tang C; Liu S; Wei Q; Duan R; Guo J; Yang L
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.
    Børretzen A; Gravdal K; Haukaas SA; Mannelqvist M; Beisland C; Akslen LA; Halvorsen OJ
    J Pathol Clin Res; 2021 May; 7(3):253-270. PubMed ID: 33605548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients.
    Parol M; Gzil A; Bodnar M; Grzanka D
    J Transl Med; 2021 Jan; 19(1):28. PubMed ID: 33413466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer.
    Yin X; Fang T; Wang Y; Wang Y; Zhang D; Li C; Xue Y
    Cancer Med; 2021 Feb; 10(3):1103-1119. PubMed ID: 33410261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.
    Chen QH; Li B; Liu DG; Zhang B; Yang X; Tu YL
    Cancer Cell Int; 2020; 20():394. PubMed ID: 32821247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy.
    Sun NY; Yang MH
    Front Oncol; 2020; 10():792. PubMed ID: 32509584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8
    Li R; Zhang H; Cao Y; Liu X; Chen Y; Qi Y; Wang J; Yu K; Lin C; Liu H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
    Cancer Immunol Immunother; 2020 Jul; 69(7):1327-1336. PubMed ID: 32200421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
    Zahm CD; Johnson LE; McNeel DG
    Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.